Medivation and Astellas Pharma US have begun a Phase II trial evaluating the safety and efficacy of enzalutamide in combination with exemestane in women with advanced breast cancer that is estrogen receptor positive (ER+) or progesterone receptor positive (PgR+) and human epidermal growth factor receptor 2 (HER2) normal. The Phase II study is a randomized, double-blind, placebo-controlled, multicenter trial of enzalutamide in combination with exemestane versus placebo plus exemestane in 240 pos...